


Package Leaflet: Information for the Patient
Avastin 25mg/ml concentrate for solution for infusion
bevacizumab
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack:
The active substance of Avastin is bevacizumab, a humanized monoclonal antibody (a type of protein that is normally produced by the immune system to help the body defend itself against infections and cancer). Bevacizumab selectively binds to a protein called vascular endothelial growth factor (VEGF), which is located on the walls of blood and lymphatic vessels in the body. The VEGF protein causes blood vessels to grow into the tumor, supplying it with nutrients and oxygen. When bevacizumab binds to VEGF, it prevents tumor growth by blocking the growth of blood vessels, which provide the necessary nutrients and oxygen for the tumor.
Avastin is a medicine used to treat adult patients with advanced colon or rectal cancer. Avastin will be given in combination with a chemotherapy treatment that contains a fluoropyrimidine medicine.
Avastin is also used to treat adult patients with metastatic breast cancer. When used in patients with breast cancer, it will be given with a chemotherapy medicine called paclitaxel or capecitabine.
Avastin is also used to treat adult patients with advanced non-small cell lung cancer. Avastin will be given along with a platinum-based chemotherapy regimen.
Avastin is also used to treat adult patients with advanced non-small cell lung cancer when the cancer cells have specific mutations in a protein called epidermal growth factor receptor (EGFR). Avastin will be given in combination with erlotinib.
Avastin is also used to treat adult patients with advanced kidney cancer. When used in patients with kidney cancer, it will be given with another type of medicine called interferon.
Avastin is also used to treat adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. When used in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, it will be given in combination with carboplatin and paclitaxel.
When used in adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had a recurrence of their disease at least 6 months after their last treatment with a platinum-based chemotherapy regimen, Avastin will be given in combination with carboplatin and gemcitabine or with carboplatin and paclitaxel.
When used in adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had a recurrence of their disease at least 6 months after their last treatment with a platinum-based chemotherapy regimen, Avastin will be given in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin.
Avastin is also used to treat adult patients with persistent, recurrent, or metastatic cervical cancer. Avastin will be given in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum-based therapy.
Do not use Avastin
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start using Avastin
Please consult your doctor even if any of the above situations affect you or have occurred in the past.
Before starting treatment with Avastin or during treatment with Avastin:
Before you start treatment with Avastin, you may be advised to have a dental check-up.
Children and adolescents
Avastin is not recommended for use in children and adolescents under 18 years of age, as the safety and efficacy in these patients have not been established.
There have been reports of bone tissue death (osteonecrosis) in bones other than the jaw in patients under 18 years of age treated with Avastin.
Other medicines and Avastin
Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use any other medicines.
The combination of Avastin with another medicine called sunitinib malate (prescribed for kidney or gastrointestinal cancer) may cause serious side effects. Consult your doctor to ensure that you do not combine these medicines.
Consult your doctor if you are receiving platinum-based or taxane-based treatment for metastatic breast or lung cancer. These therapies in combination with Avastin may increase the risk of serious side effects.
Tell your doctor if you have recently received or are receiving radiation therapy.
Pregnancy, breastfeeding, and fertility
Do not use Avastin if you are pregnant. Avastin may harm your unborn baby, as it may prevent the formation of new blood vessels. Your doctor should advise you to use a contraceptive method during treatment with Avastin and for at least 6 months after the last dose of Avastin.
Inform your doctor immediately if you are already pregnant, become pregnant during treatment with Avastin, or plan to become pregnant in the near future.
Do not breastfeed your baby during treatment with Avastin and for at least 6 months after the last dose of Avastin, as this medicine may interfere with the growth and development of your baby.
Avastin may affect female fertility. Consult your doctor for more information.
Consult your doctor, pharmacist, or nurse before using any medicine.
Driving and using machines
Avastin has not been shown to reduce your ability to drive or use tools or machines. However, somnolence and fainting have been reported with the use of Avastin. If you experience symptoms that affect your vision or concentration, or your reaction ability, do not drive or use machines until the symptoms disappear.
Important information about some of the ingredients of Avastin
Avastin contains sodiumThis medicine contains less than 1 mmol of sodium (23 mg) per vial, which is essentially "sodium-free".
Dose and frequency of administration
The dose of Avastin needed depends on your weight and the type of cancer being treated. The recommended dose is 5 mg, 7.5 mg, 10 mg, or 15 mg per kilogram of body weight. Your doctor will prescribe the most suitable dose of Avastin for you, and you will be treated with Avastin once every 2 or 3 weeks. The number of infusions you receive will depend on how you respond to treatment and should continue until Avastin no longer slows down tumor growth. Your doctor will discuss these aspects with you.
Form and route of administration
Do not shake the vial.
Avastin is a concentrate for solution for infusion. Depending on the dose prescribed for you, a fraction or all of the contents of the Avastin vial will be diluted with sodium chloride solution before administration. A doctor or nurse will give you this diluted Avastin solution as an intravenous infusion (by drip into your veins). The first infusion will be given over 90 minutes. If you tolerate this infusion well, the second infusion can be given over 60 minutes. Subsequent infusions can be given over 30 minutes.
Administration of Avastin should be temporarily interrupted:
Administration of Avastin should be permanently discontinued if you have:
If you use more Avastin than you should
If you forget to use Avastin
If you stop using Avastin
Stopping treatment with Avastin may reduce its effect on tumor growth. Do not stop treatment with Avastin unless you have discussed it with your doctor.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people will experience them.
If you experience adverse effects, consult your doctor, pharmacist, or nurse, even if they are adverse effects that do not appear in this leaflet.
The adverse effects mentioned below have been observed when Avastin is administered with chemotherapy. This does not necessarily mean that these adverse effects were strictly caused by Avastin.
Allergic Reactions
If you have an allergic reaction, consult your doctor or healthcare professional immediately. The signs may include: difficulty breathing or chest pain. You may also experience redness or flushing of the skin or rash, chills and tremors, feeling of dizziness (nausea) or feeling of discomfort (vomiting), swelling, dizziness, rapid heartbeat, loss of consciousness.
You should seek help immediately if you suffer from any of the adverse effects mentioned below.
Severe adverse effects that may be very common(may affect more than 1 in 10 patients) include:
Severe adverse effects that may be common(may affect up to 1 in 10 patients) include:
Severe adverse effects that may be rare(may affect up to 1 in 1000 patients) include:
Severe adverse effects of unknown frequency(cannot be estimated from the available data) include:
If you notice any of these adverse effects, seek medical attention as soon as possible.
Adverse effects that are very common(may affect more than 1 in 10 patients) and not severe are:
Adverse effects that are common(may affect up to 1 in 10 patients) and not severe are:
Patient over 65 years of age have a higher risk of experiencing the following:
Avastin may also cause changes in laboratory tests that your doctor performs. These changes may include a decrease in the number of white blood cells in the blood, particularly neutrophils (a type of white blood cell that helps fight infections), presence of protein in the urine, decrease in potassium, sodium, or phosphorus in the blood, increase in blood sugar, increase in alkaline phosphatase (an enzyme) in the blood, decrease in hemoglobin (which is found in red blood cells and carries oxygen), which may be severe.
Pain in the mouth, teeth, and/or jaw, swelling or sores in the mouth, numbness or feeling of heaviness of the jaw, or loss of a tooth. These may be signs and symptoms of jawbone damage (osteonecrosis). Inform your doctor and dentist immediately if you experience any of them.
Pre-menopausal women (women who have a menstrual cycle) may notice that their periods become irregular or disappear and may experience fertility problems. If you are thinking of having children, you should consult your doctor before starting treatment.
Avastin has been developed and manufactured to treat cancer by injection into the bloodstream. It has not been developed or manufactured for injection into the eye. Therefore, it is not authorized for use in this way. When Avastin is injected directly into the eye (unapproved use), the following side effects may occur:
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and on the label of the vial after CAD. The expiration date is the last day of the month indicated.
Store in a refrigerator (between 2°C and 8°C).
Do not freeze.
Keep the vial in the outer packaging to protect it from light.
The solution for infusion should be administered immediately after dilution. If it is not administered immediately, the storage times and conditions are the responsibility of the user and would normally not be more than 24 hours at between 2°C and 8°C, unless the infusion solutions have been prepared in a sterile environment. When the dilution has been prepared in a sterile environment, Avastin remains stable for 30 days at between 2°C and 8°C plus an additional 48 hours at between 2°C and 30°C.
Do not use Avastin if you observe foreign particles or discoloration before administration.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Avastin
The active substance is bevacizumab.
Each 4 ml vial contains 100 mg of bevacizumab, corresponding to 1.4 mg/ml when diluted as recommended.
Each 16 ml vial contains 400 mg of bevacizumab, corresponding to 16.5 mg/ml when diluted as recommended.
Appearance and Package Contents
Avastin is a concentrate for solution for infusion. The concentrate is a clear, colorless to pale brown liquid contained in a glass vial with a rubber stopper. Each vial contains either 100 mg of bevacizumab in 4 ml of solution or 400 mg of bevacizumab in 16 ml of solution. Each package of Avastin contains one vial.
Marketing Authorization Holder
Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany
Manufacturer
Roche Pharma AG
Emil-Barell-Str. 1
79639 Grenzach-Wyhlen
Germany
You can obtain more information about this medicine by contacting the local representative of the marketing authorization holder:
Belgium N.V. Roche S.A. Tel: +32 (0) 2 525 82 11 | Lithuania UAB “Roche Lietuva” Tel.: +370 5 2546799 |
Bulgaria Roche Bulgaria EOOD Tel: +359 2 818 44 44 | Luxembourg (See Belgium) |
Czech Republic Roche s. r. o. Tel.: +420 - 2 20382111 | Hungary Roche (Magyarország) Kft. Tel.: +36 - 1 279 4500 |
Denmark Roche Pharmaceuticals A/S Tel.: +45 - 36 39 99 99 | Malta (See Ireland) |
Germany Roche Pharma AG Tel.: +49 (0) 7624 140 | Netherlands Roche Nederland B.V. Tel.: +31 (0) 348 438050 |
Estonia Roche Eesti OÜ Tel.: + 372 - 6 177 380 | Norway Roche Norge AS Tel.: +47 - 22 78 90 00 |
Greece Roche (Hellas) A.E. Tel.: +30 210 61 66 100 | Austria Roche Austria GmbH Tel.: +43 (0) 1 27739 |
Spain Roche Farma S.A. Tel.: +34 - 91 324 81 00 | Poland Roche Polska Sp.z o.o. Tel.: +48 - 22 345 18 88 |
France Roche Tel: +33 (0) 1 47 61 40 00 | Portugal Roche Farmacêutica Química, Lda Tel.: +351 - 21 425 70 00 |
Croatia Roche d.o.o. Tel.: +385 1 4722 333 | Romania Roche România S.R.L. Tel.: +40 21 206 47 01 |
Ireland Roche Products (Ireland) Ltd. Tel.: +353 (0) 1 469 0700 | Slovenia Roche farmacevtska družba d.o.o. Tel.: +386 - 1 360 26 00 |
Iceland Roche Pharmaceuticals A/S c/o Icepharma hf Tel: +354 540 8000 | Slovakia Roche Slovensko, s.r.o. Tel.: +421 - 2 52638201 |
Italy Roche S.p.A. Tel.: +39 - 039 2471 | Finland Roche Oy Tel: +358 (0) 10 554 500 |
Cyprus Γ.Α.Σταμ?της & Σια Λτδ. Tel.: +357 - 22 76 62 76 | Sweden Roche AB Tel.: +46 (0) 8 726 1200 |
Latvia Roche Latvija SIA Tel.: +371 - 6 7039831 | United Kingdom (Northern Ireland) Roche Products (Ireland) Ltd. Tel: +44 (0) 1707 366000 |
Date of Last Revision of this Leaflet
Other Sources of Information
Detailed information about this medicine is available on the European Medicines Agency website http://www.ema.europa.eu.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for AVASTIN 25 mg/mL concentrate for infusion solution – subject to medical assessment and local rules.